The ratings of 11 Pharmaceuticals stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Novartis AG Sponsored ADR’s (NVS) rating weakens this week, dropping to a F versus last week’s D. Novartis AG Sponsored ADR manufactures pharmaceutical and consumer healthcare products. For more information, get Portfolio Grader’s complete analysis of NVS stock.

Phibro Animal Health Corporation Class A (PAHC) experiences a ratings drop this week, going from last week’s C to a D. For more information, get Portfolio Grader’s complete analysis of PAHC stock.

This week, Catalent Inc’s (CTLT) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of CTLT stock.

Paratek Pharmaceuticals Inc (PRTK) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PRTK stock.

MediWound Ltd. (MDWD) declines this week from a C to a D. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of MDWD stock.

This is a rough week for Nabriva Therapeutics AG Sponsored ADR (NBRV). The company’s rating falls to F from the previous week’s D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of NBRV stock.

Flex Pharma, Inc. (FLKS) slips from a C to a D this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of FLKS stock.

This week, Alcobra Ltd. (ADHD) drops from a D to a F rating. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ADHD stock.

Alimera Sciences, Inc. (ALIM) is having a tough week. The company’s rating falls from a C to a D. Alimera Sciences, Inc. engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company also gets F’s in free cash flow. For more information, get Portfolio Grader’s complete analysis of ALIM stock.

Slipping from a D to a F rating, Acura Pharmaceuticals, Inc. (ACUR) takes a hit this week. Acura Pharmaceuticals, Inc. engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ACUR stock.

Bio-Path Holdings, Inc. (BPTH) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of BPTH stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.